Key Highlights

  • Order book more than doubled to £65m from £30m at the start of the year
  • Proposal volumes up approximately 45% year on year
  • H1 2026 Revenue fell to £16.3m from £24.2m on trial delivery timing
  • Adjusted EBITDA swung negative in H1, with a return to positive EBITDA guided for H2
  • Cash stood at £13m at 30 June 2026, down sharply from £44.2m at the end of 2024
  • Full-year guidance maintained at high single-digit revenue growth on a £46.8m 2025 base

hVIVO (LSE:HVO), the London-based contract research organisation that runs human challenge trials — deliberately infecting volunteers to test vaccines and antivirals — has spent 2026 rebuilding after a difficult 2025. Its 23 July trading update delivered the clearest evidence yet of a recovery in commercial momentum: a contracted order book that has more than doubled to £65m, and a pipeline of proposals running well ahead of the prior year. The catch is that almost all of the payoff is loaded into the second half, making the coming months a critical test of execution.

What Has Happened?

In its H1 2026 trading update, hVIVO said its order book stood at around £65m, up from roughly £30m at the start of the year. That rebuild followed a period of trial cancellations and deferrals that had hollowed out revenue in 2025. Management reported proposal volumes up approximately 45% year on year and pointed to contract momentum across its service lines, including a £6m influenza human challenge trial signed in May 2026.

Crucially, the company reiterated that 2026 revenue would be heavily weighted to the second half, and that it expected to return to positive adjusted EBITDA in H2 after a loss-making first half. It flagged that modest amounts of second-half revenue could slip into 2027, but maintained its full-year guidance of high single-digit revenue growth.

The Numbers Investors Need to Know

First-half revenue came in at £16.3m, down sharply from £24.2m in the same period of 2025, reflecting the timing of trial delivery rather than lost demand. Adjusted EBITDA swung to a negative mid-single-digit-million figure, against a positive £3.0m a year earlier. Cash stood at £13m at 30 June 2026, little changed from £14.3m at the end of December 2025.

The backdrop is a weak 2025. For the year to 31 December 2025, hVIVO reported revenue of £46.8m, down from £62.7m, with adjusted EBITDA collapsing to £1.4m from £16.4m and cash falling to £14.3m from £44.2m. The order book closed 2025 at £30m. Against that base, high single-digit growth in 2026 implies a full-year figure of roughly £50m — a total that can only be reached if the second half delivers materially more than the first. The board paid no Dividend for 2025, prioritising reinvestment.

Why This Matters

The order book is the single most important forward indicator for a challenge-trial business, because revenue is recognised as studies are delivered rather than when contracts are signed. Doubling contracted work to £65m therefore restores the revenue visibility that evaporated during 2025's wave of cancellations. It suggests biopharma clients, having paused programmes amid tighter funding, are returning to the pipeline.

For investors, the update reframes the story from "structural decline" to "timing and recovery". The heavy H2 weighting is a double-edged feature: it underpins the full-year guidance, but it also concentrates delivery risk into a narrow window. The guided return to positive EBITDA in the second half is the number that will validate — or undermine — the recovery thesis.

The scale of the required swing is worth spelling out. First-half revenue of £16.3m against high-single-digit full-year growth on a £46.8m 2025 base implies a second half comfortably larger than the first — a demanding profile for a Business whose revenue is recognised only as studies run. That is why the order book, rather than the depressed H1 numbers, is the figure the market is watching: at £65m it provides the contracted Backlog needed to underwrite the back-loaded plan, provided the studies are delivered on schedule.

What Is Driving the Story?

Several forces are at work. First, a broader thaw in biopharma spending after a cautious period, reflected in the roughly 45% jump in proposal volumes. Second, hVIVO's diversification: recent acquisitions in clinical services broadened the platform beyond its core challenge-trial Franchise and contributed to the group in 2025, with management expecting them to become earnings-accretive during 2026. Third, expansion of the challenge-model menu itself — new pathogens and study designs widen the addressable pipeline across the group's service lines.

Together these factors have converted a depleted 2025 order book into a stronger 2026 position, giving management the confidence to reaffirm growth even after a soft first half.

What Could Drive the Shares Next?

The pivotal catalyst is the delivery of that second-half revenue and the return to positive adjusted EBITDA. Interim results, expected in September, will provide the first detailed read on margins, cash and how much of the £65m order book is scheduled to convert before year-end. Confirmation that H2 is tracking to plan — with limited slippage into 2027 — would be the strongest support for sentiment.

Beyond the current year, further large contract wins, continued growth in proposal volumes, and evidence that the acquired clinical-services operations are becoming accretive would all matter. A rebuilt order book heading into 2027 would signal that the recovery has durability rather than being a one-year catch-up.

Risks Investors Should Watch

The clearest risk is execution against the second-half weighting. If studies slip — a recurring feature of clinical trial timing — more revenue could defer into 2027 than currently expected, pressuring full-year delivery. hVIVO's history of cancellations in 2025 shows how quickly visibility can erode.

Cash is another watch point: at £13m, the Balance Sheet is adequate but no longer the fortress it was after 2024, having fallen from £44.2m. A loss-making first half consumes headroom. Client concentration, sensitivity to biopharma funding cycles, and the absence of a dividend add to the risk profile. The recovery is credible but not yet proven.

The Bottom Line

hVIVO's doubling of its order book to £65m is a genuine turning point in a story that looked bleak a year ago, restoring the revenue visibility that a challenge-trial business lives on. But the recovery is back-end loaded, and the recovery case now rests on the second half delivering the growth and the return to positive EBITDA that management has guided to. Investors should treat the September interims and subsequent trading updates as the real proof points. The Demand signals are encouraging; the execution has yet to be banked.